tirzepatide and binge eating disorder for Disorder: Evidence Considerations Novel potential pharmacological approaches in

2016;10(1 Suppl 1):S1446

[1] [4] It represents a novel therapeutic class as the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist

Such subtle effects may reflect functional adaptations of mitochondria to conditions that require ATP generation or energy dissipation

Paradoxically, these findings indicate that similar results can be obtained by combining GLP-1 receptor activation with either GIP receptor agonism or GIP receptor antagonism

For those uninsured, our staff discusses diverse options to facilitate access to care, ensuring cost is not a barrier to effective weight management